Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are pleased to present the latest issue of touchREVIEWS in Endocrinology, which offers a timely and thoughtprovoking collection of articles that reflect both the continuity and evolution of diabetes and metabolic disease research. In an era where technology, public health priorities and clinical paradigms are shifting rapidly, this issue highlights the importance of evidence-based […]

Rifaat Safadi, EASL 2023: CM-101 for the treatment of non-alcoholic steatohepatitis – aims and design

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Aug 1st 2023

CM-101, a CCL24 neutralizing antibody, has been recently studied in patients with non-alcoholic steatohepatitis in a phase IIa proof-of-concept study. In this touchENDOCRINOLOGY interview, we caught up with Prof Rifaat Safadi (The Liver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel) to discuss the mechanism of action of CM-101, and the aims, design and eligibility criteria of the proof-of-concept study.

The abstract entitled ‘Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with nonalcoholic steatohepatitis: a proof-of-concept study‘ was presented at EASL 2023, 21–24 June 2023, Vienna, Austria.

Questions:

  1. What is the mechanism of action of CM-101? (0:14)
  2. What were the aims, design, and eligibility criteria of the study? (2:03)

Disclosures: Rifaat Safadi is a consultant for Chemomab.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Atiya Henry.

Filmed in coverage of EASL 2023

Access further content on liver disorders

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup